Servier India Launches First-in-Class Targeted Therapy ‘Ivosidenib’ for Rare IDH1-Mutated AML and Cholangiocarcinoma
Servier India, a fully owned affiliate of the France-based Servier Group, has announced the launch of Ivosidenib (Tibsovo®)—a precision, first-in-class […]
